SELECT PUBLICATIONS

Browall M et al. Postmenopausal women with breast cancer: Their experiences of the chemotherapy treatment period. Cancer Nurs 2006;29(1):34-42. Abstract

Carlson RW et al; National Comprehensive Cancer Network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.J Natl Compr Canc Netw 2006;4(Suppl 1):1-26. Abstract

Colditz GA et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96(3):218-28. Abstract

Duric VM et al. Patients’ preferences for adjuvant endocrine therapy in early breast cancer: What makes it worthwhile? Br J Cancer 2005;93(12):1319-23. Abstract

Fallowfield L et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol2006;17(2):205-10. Abstract

Forrest G et al. Breast cancer in the family — Children's perceptions of their mother's cancer and its initial treatment: Qualitative study. BMJ 2006;332(7548):998-1003. Abstract

Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. Eur J Oncol Nurs 2004;8(Suppl 1):63-71. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Gray RE et al. Supportive care provided by physicians and nurses to women with breast cancer. Results from a population-based survey. Support Care Cancer 2002;10(8):647-52. Abstract

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

HERA Study Team. Trastuzumab (H: Herceptin®) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 11. 

Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Lengacher CA et al. Relief of symptoms, side effects, and psychological distress through use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 2006;33(1):97-104. Abstract

Lynn J. The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer — Focus on fulvestrant. Cancer Nurs 2002;25(Suppl 2):12-7. Abstract

Mamounas E et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20.Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 29.

Marse H et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):16-30. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol2005;23(4):792-9. Abstract

Olivotto IA et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer.J Clin Oncol2005;23(12):2716-25. Abstract

O’Shaughnessy J et al. ABI-007 (ABRAXANE™), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.

Owers R. Clinical experience with fulvestrant ('Faslodex'): A nurse's perspective. Eur J Oncol Nurs 2004;8(Suppl 2):89-94. Abstract

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004a;351(27):2817-26. Abstract

Paik S et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Presentation. San Antonio Breast Cancer Symposium 2004b;Abstract 24.

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.

Robert N et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2073.

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials.Cancer 2003;98(2):229-38. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Slamon D et al, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Sternberg CN et al. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs 2004;8(Suppl 1):4-15. Abstract

Vogel WH. The advanced practice nursing role in a high-risk breast cancer clinic. Oncol Nurs Forum 2003;30(1):115-22. Abstract